<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01525069</url>
  </required_header>
  <id_info>
    <org_study_id>201111068</org_study_id>
    <nct_id>NCT01525069</nct_id>
  </id_info>
  <brief_title>Hepatic Arterial Infusion in Treating Patients With Locally Advanced, Non-Metastatic Cholangiocarcinoma</brief_title>
  <official_title>Pilot Study of Hepatic Arterial Infusion Therapy in Patients With Unresectable or Borderline Resectable Intrahepatic Cholangiocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot clinical trial studies the safety and effectiveness of continuous hepatic arterial
      infusion (HAI) of floxuridine (FUDR) alone or in combination with other chemotherapeutic
      drugs in treating patients with locally advanced cholangiocarcinoma that cannot be removed by
      surgery. HAI is a method to deliver higher concentrations of FUDR more directly to liver
      tumors and reduces side effects. HAI alone or in combination with oxaliplatin and/or
      gemcitabine may significantly improve clinical outcomes of patients with locally advanced
      cholangiocarcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 3, 2012</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicities (DLTs)</measure>
    <time_frame>Completion of 2 cycles of treatment by all patients (approximately 4 years)</time_frame>
    <description>Document the frequency of grades 3-5 non-hematologic toxicities (dose-limiting toxicities) associated with the treatment regimen by patient and by type of toxicity for each cohort during the first 2 cycles of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression (TTP)</measure>
    <time_frame>12 months</time_frame>
    <description>Describe median time to progression with a 95% confidence interval for each cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rates</measure>
    <time_frame>8 weeks</time_frame>
    <description>The best overall response is the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the treatment started)
Using RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and grade of adverse events</measure>
    <time_frame>Beginning with pump placement and continuing for 30 days following the last day of study treatment (median length of treatment 3 months)</time_frame>
    <description>Determine safety, tolerability and toxicities based on the number and grade of adverse events associated with this regimen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Imaging biomarkers of tumor response</measure>
    <time_frame>Pre-treatment and then every 8 weeks during treatment (median length of treatment 3 months)</time_frame>
    <description>Using magnetic resonance diffusion-weighted imaging (DW-MRI) and dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) before and during the course of treatment with HAI therapy, validate imaging biomarkers of tumor response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression (TTP)</measure>
    <time_frame>24 months</time_frame>
    <description>Describe median time to progression with a 95% confidence interval for each cohort.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">57</enrollment>
  <condition>Cholangiocarcinoma</condition>
  <condition>Liver Neoplasms</condition>
  <arm_group>
    <arm_group_label>Arm A (HAI FUDR alone)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>14-42 days after surgery for insertion of the HAI pump, floxuridine (FUDR) and dexamethasone plus heparin in normal saline to a total volume of 30 ml will be administered through the HAI pump.
This will be repeated on Day 1 of each 28 day cycle. FUDR administration will be a 14-day continuous infusion using the HAI pump.
The pump will be emptied and refilled with heparinized normal saline and dexamethasone on Day 15 of each cycle to be infused over the next 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (HAI FUDR + gemcitabine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Consists of Cohort B1, B2, and B3. Enrollment to specific cohorts will depend on the number of DLTs in each cohort. Each cohort has a different dose of FUDR and gemcitabine.
Gemcitabine IV will be given on Days 1, 8, and 15 of each 28 day cycle in Cohort B1
Gemcitabine IV will be given on Days 1 and 15 of each 28 day cycle in Cohort B2 &amp; B3
14-42 days after surgery for insertion of the HAI pump, floxuridine (FUDR) and dexamethasone plus heparin in normal saline to a total volume of 30 ml will be administered through the HAI pump.
This will be repeated on Day 1 of each 28 day cycle. FUDR administration will be a 14-day continuous infusion using the HAI pump.
The pump will be emptied and refilled with heparinized normal saline and dexamethasone on Day 15 of each cycle to be infused over the next 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C (HAI FUDR + gemcitabine + oxaliplatin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Consists of Cohort C1, C2, C3, and C4. Enrollment to specific cohorts will depend on the number of DLTs in each cohort. Each cohort has a different dose of FUDR, gemcitabine, and oxaliplatin.
Gemcitabine IV will be given on Days 1 and 15 of each 28 day cycle.
Oxaliplatin IV will be given on Days 1 and 15 of each 28 days cycle.
14-42 days after surgery for insertion of the HAI pump, floxuridine (FUDR) and dexamethasone plus heparin in normal saline to a total volume of 30 ml will be administered through the HAI pump.
This will be repeated on Day 1 of each 28 day cycle. FUDR administration will be a 14-day continuous infusion using the HAI pump.
The pump will be emptied and refilled with heparinized normal saline and dexamethasone on Day 15 of each cycle to be infused over the next 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Floxuridine</intervention_name>
    <arm_group_label>Arm A (HAI FUDR alone)</arm_group_label>
    <arm_group_label>Arm B (HAI FUDR + gemcitabine)</arm_group_label>
    <arm_group_label>Arm C (HAI FUDR + gemcitabine + oxaliplatin)</arm_group_label>
    <other_name>5-FUDR, FdUrD, floxuridin, fluorodeoxyuridine, fluoruridine deoxyribose, FUdR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <arm_group_label>Arm A (HAI FUDR alone)</arm_group_label>
    <arm_group_label>Arm B (HAI FUDR + gemcitabine)</arm_group_label>
    <arm_group_label>Arm C (HAI FUDR + gemcitabine + oxaliplatin)</arm_group_label>
    <other_name>Aeroseb-Dex, Decaderm, Decadron, Decaspray, DM, DXM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <arm_group_label>Arm B (HAI FUDR + gemcitabine)</arm_group_label>
    <arm_group_label>Arm C (HAI FUDR + gemcitabine + oxaliplatin)</arm_group_label>
    <other_name>dFdC, dFdCyd, difluorodeoxycytidine hydrochloride, gemcitabine, Gemzar, LY-188011</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <arm_group_label>Arm C (HAI FUDR + gemcitabine + oxaliplatin)</arm_group_label>
    <other_name>1-OHP, Dacotin, Dacplat, diaminocyclohexane oxalatoplatinum, Eloxatin, L-OHP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient must have suspected intrahepatic or hilar cholangiocarcinoma with minimal
             extrahepatic disease. Diagnosis must be histologically or cytologically confirmed for
             continued treatment on study after pump placement.

          -  Patient must have measurable disease, defined as at least one lesion that can be
             accurately measured in at least one dimension (longest diameter to be recorded) as &gt;=
             20 mm with conventional techniques or as &gt;= 10 mm with spiral computed tomography (CT)
             scan/MRI

          -  Patient must have disease that is unresectable or borderline resectable with &lt; 70%
             liver involvement by cancer

          -  Patient must be &gt;= 18 years old.

          -  Patient's Eastern Cooperative Oncology Group (ECOG) performance status must be =&lt; 2
             (Karnofsky &gt;= 60%)

          -  Patient must have normal organ and marrow function as defined below:

               -  Absolute neutrophil count &gt;= 1,500/mcL

               -  Platelets &gt;= 75,000/mcL

               -  Total bilirubin =&lt; 2 mg/dL

               -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
                  [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase
                  [SGPT]) =&lt; 5 X institutional upper limit of normal

               -  Creatinine &lt;= institutional upper limit normal

          -  Patient must be able to understand and willing to sign a written informed consent
             document

        Exclusion Criteria:

          -  Patients must not have had prior treatment with FUDR

          -  Patient must not be receiving any other investigational agents

          -  Patient must not have a diagnosis of Gilbert's disease

          -  Patient must not have a diagnosis of hepatic encephalopathy

          -  Patient must not have had prior external beam radiation to the liver

          -  Patient must not have a diagnosis of sclerosing cholangitis

          -  Patient must not have any uncontrolled intercurrent illness including, but not limited
             to, ongoing or active infection, symptomatic congestive heart failure, unstable angina
             pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would
             limit compliance with study requirements

          -  Patient must not be pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Chapman, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>William Chapman, M.D.</last_name>
    <phone>314-362-7792</phone>
    <email>chapmanw@wustl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tracey Guthrie</last_name>
    <phone>314-747-4404</phone>
    <email>guthriet@wustl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Chapman, M.D.</last_name>
      <phone>314-362-7792</phone>
      <email>chapmanw@wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Tracey Guthrie</last_name>
      <phone>314-747-4404</phone>
      <email>guthriet@wustl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>William Chapman, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>M.B. Majella Doyle, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>William Hawkins, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeffrey Lowell, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joel Picus, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steven Strasberg, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rama Suresh, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrea Wang-Gillam, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kathryn J. Fowler, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benjamin Tan, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Kotyk, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <reference>
    <citation>Valle JW WH, Palmer DD, Cunningham D, Anthoney DA, Maraveyas A, Hughes SK, Roughton JA, Bridgewater JA: Gemcitabine with or without cisplatin in patients (pts) with advanced or metastatic biliary tract cancer (ABC): Results of a multicenter, randomized phase III trial (the UK ABC-02 trial). J Clin Oncol 27:15s, 2009 (suppl, abstr 4503), 2009</citation>
  </reference>
  <reference>
    <citation>Tan BR, Brenner WS, Picus J, Marsh S, Gao F, Fournier C, Fracasso PM, James J, Yen-Revollo JL, McLeod HL. Phase I study of biweekly oxaliplatin, gemcitabine and capecitabine in patients with advanced upper gastrointestinal malignancies. Ann Oncol. 2008 Oct;19(10):1742-8. doi: 10.1093/annonc/mdn375. Epub 2008 Jun 4.</citation>
    <PMID>18534963</PMID>
  </reference>
  <reference>
    <citation>Kemeny NE, Melendez FD, Capanu M, Paty PB, Fong Y, Schwartz LH, Jarnagin WR, Patel D, D'Angelica M. Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol. 2009 Jul 20;27(21):3465-71. doi: 10.1200/JCO.2008.20.1301. Epub 2009 May 26.</citation>
    <PMID>19470932</PMID>
  </reference>
  <reference>
    <citation>Kemeny NE, Gonen M. Hepatic arterial infusion after liver resection. N Engl J Med. 2005 Feb 17;352(7):734-5.</citation>
    <PMID>15716576</PMID>
  </reference>
  <reference>
    <citation>Jarnagin WR, Schwartz LH, Gultekin DH, GÃ¶nen M, Haviland D, Shia J, D'Angelica M, Fong Y, Dematteo R, Tse A, Blumgart LH, Kemeny N. Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. Ann Oncol. 2009 Sep;20(9):1589-95. doi: 10.1093/annonc/mdp029. Epub 2009 Jun 2.</citation>
    <PMID>19491285</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2012</study_first_submitted>
  <study_first_submitted_qc>January 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2012</study_first_posted>
  <last_update_submitted>March 22, 2018</last_update_submitted>
  <last_update_submitted_qc>March 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Floxuridine</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

